Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipel⦠read more
Healthcare
Biotechnology
25 years
USD
Exclusive to Premium users
$2.26
Price+1.35%
$0.03
$179.743m
Small
25.1x
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$61.948m
-
1y CAGR-
3y CAGR-
5y CAGR$6.275m
-
1y CAGR-
3y CAGR-
5y CAGR$0.07
-
1y CAGR-
3y CAGR-
5y CAGR$49.903m
$78.486m
Assets$28.583m
Liabilities$5.349m
Debt6.8%
0.5x
Debt to EBITDA-$3.444m
-
1y CAGR-
3y CAGR-
5y CAGR